Maze Therapeutics (NASDAQ:MAZE) Upgraded at Leerink Partnrs
Leerink Partnrs upgraded shares of Maze Therapeutics (NASDAQ:MAZE – Free Report) to a strong-buy rating in a report released on Tuesday,Zacks.com reports. Leerink Partnrs also issued estimates for Maze Therapeutics’ Q4 2024 earnings at ($7.60) EPS, FY2024 earnings at ($4.93) EPS, Q1 2025 earnings at ($0.58) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 […]
Leerink Partnrs upgraded shares of Maze Therapeutics (NASDAQ:MAZE – Free Report) to a strong-buy rating in a report released on Tuesday,Zacks.com reports. Leerink Partnrs also issued estimates for Maze Therapeutics’ Q4 2024 earnings at ($7.60) EPS, FY2024 earnings at ($4.93) EPS, Q1 2025 earnings at ($0.58) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 […]
